Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Minini

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Biostatistics (Oxford, England)|October 12, 2004
Sensitivity analysis of longitudinal binary data with non-monotone missing valuesPascal Minini, Michel Chavance
Statistics in Medicine|April 2, 2004
Sensitivity analysis of longitudinal normal data with drop-outsPascal Minini, Michel Chavance
Medecine Sciences : M/S|March 5, 2004
[Multiplicity of inferences in clinical trials: adjustment methods, clinical interpretation issues]Chrystel Jouan-Flahault, Florence Casset-Semanaz, Pascal Minini
Pediatrics|June 5, 2003
Long-term safety of fluticasone propionate and nedocromil sodium on bone in children with asthmaChristian Roux, Sami Kolta, Jean-Luc Desfougères, et al.
International Journal of Cardiology|August 31, 2016
Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trialsMichel Farnier, Daniel Gaudet, Velichka Valcheva, et al.
Chest|March 19, 2011
Bleeding risk in patients with atrial fibrillation: the AMADEUS studyDeirdre A Lane, Pieter W Kamphuisen, Pascal Minini, et al.
Journal of Hepatology|June 15, 2010
Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosisFlorence Wong, Pere Gines, Hugh Watson, et al.
The American Journal of Cardiology|October 30, 2016
Effect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program)Daniel Gaudet, Gerald F Watts, Jennifer G Robinson, et al.
Circulation|October 26, 2016
Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With ControlKausik K Ray, Henry N Ginsberg, Michael H Davidson, et al.
Coronary Artery Disease|October 15, 2016
Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemiaJohn J P Kastelein, Dean J Kereiakes, Christopher P Cannon, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Biostatistics (Oxford, England)|October 12, 2004
Sensitivity analysis of longitudinal binary data with non-monotone missing valuesPascal Minini, Michel Chavance
Statistics in Medicine|April 2, 2004
Sensitivity analysis of longitudinal normal data with drop-outsPascal Minini, Michel Chavance
Medecine Sciences : M/S|March 5, 2004
[Multiplicity of inferences in clinical trials: adjustment methods, clinical interpretation issues]Chrystel Jouan-Flahault, Florence Casset-Semanaz, Pascal Minini
Pediatrics|June 5, 2003
Long-term safety of fluticasone propionate and nedocromil sodium on bone in children with asthmaChristian Roux, Sami Kolta, Jean-Luc Desfougères, et al.
International Journal of Cardiology|August 31, 2016
Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trialsMichel Farnier, Daniel Gaudet, Velichka Valcheva, et al.
Chest|March 19, 2011
Bleeding risk in patients with atrial fibrillation: the AMADEUS studyDeirdre A Lane, Pieter W Kamphuisen, Pascal Minini, et al.
Journal of Hepatology|June 15, 2010
Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosisFlorence Wong, Pere Gines, Hugh Watson, et al.
The American Journal of Cardiology|October 30, 2016
Effect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program)Daniel Gaudet, Gerald F Watts, Jennifer G Robinson, et al.
Circulation|October 26, 2016
Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With ControlKausik K Ray, Henry N Ginsberg, Michael H Davidson, et al.
Coronary Artery Disease|October 15, 2016
Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemiaJohn J P Kastelein, Dean J Kereiakes, Christopher P Cannon, et al.
Pageof 2